Suchen
Inovio Pharmaceuticals Inc
INOZur Watchlist hinzufügen
1.220USD
+0.030+2.52%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
84.18MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Inovio Pharmaceuticals Inc Unternehmen
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Inovio Pharmaceuticals Inc Informationen
BörsenkürzelINO
Name des UnternehmensInovio Pharmaceuticals Inc
IPO-datumDec 08, 1998
CEOShea (Jacqueline Elizabeth)
Anzahl der mitarbeiter134
WertpapierartOrdinary Share
GeschäftsjahresendeDec 08
Addresse660 W. Germantown Pike
StadtPLYMOUTH MEETING
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19462
Telefon18584103134
Websitehttps://www.inovio.com/
BörsenkürzelINO
IPO-datumDec 08, 1998
CEOShea (Jacqueline Elizabeth)
Führungskräfte von Inovio Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Inovio Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Inovio Pharmaceuticals Inc sind: Dr. Jacqueline Elizabeth Shea, Ph.D.
Wie viele Institutionen halten Anteile an Inovio Pharmaceuticals Inc (INO)?
Mit Stand vom 2026Q1 halten 266 Institutionen Anteile an Inovio Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 32.85M, was 40.31% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 3035014.00 gestiegen.